Type 2 diabetes mellitus Nutritional, Metabolic, Endocrine Type 2 diabetes mellitus
Conditions
Interventions
Potential participants will be identified from GP clinic lists, routine GP appointments, and through response to trial promotional material online and in print displayed in various public areas. Poten
Sponsors
University of Oxford
Eligibility
Sex/Gender
All
Age
35 Years to 120 Years
Inclusion criteria
Inclusion criteria: 1. Willing and able to give informed consent for participation in the trial 2. Aged =35 years 3. Diagnosis of type 2 diabetes 4. Taking oral glucose-lowering treatment, blood pressure-lowering treatment, or lipid-lowering treatment (diabetes treatments) either alone or in combination 5. Has access to a UK registered mobile phone and is able, if necessary, with help (e.g. relative, friend, neighbour), to send, understand and retrieve brief SMS text-messages in the English language 6. Registered with a general practice participating in the trial
Exclusion criteria
Exclusion criteria: 1. Pregnant, has been pregnant in the last three months or planning pregnancy during the course of the trial 2. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial 3. Insulin treatment without concomitant use of oral glucose lowering treatment 4. Admitted to hospital within the last three months for hyper- or hypoglycaemia (self-report) 5. Another person in the household already participates in this trial 6. Currently using a pharmacist managed monitored dosage system for supply of medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite cardiovascular outcome based on the UKPDS risk engine equations calculated using measures of glycated haemoglobin (HbA1c), systolic and diastolic blood pressure, high-density lipoproteins (HDL) cholesterol, and total cholesterol measured at baseline and 52 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Long term glycaemic control measured using HbA1c level in blood samples at baseline and 52 weeks 2. Systolic blood pressure measured using a sphygmomanometer at baseline and 52 weeks 3.Diastolic blood pressure measured using a sphygmomanometer at baseline and 52 weeks 4. Total and HDL cholesterol measured using blood samples at baseline and 52 weeks 5. Quality of life measured using the EQ-5D-5L questionnaire at baseline, 13, 26, and 52 weeks | — |
Countries
England, United Kingdom, Wales
Outcome results
None listed